TheraRadar
Clinical-Stage Companies / InventisBio

InventisBio

Pre-Approval PRO BETA
28
Total Trials
3
Phase 3
13
Phase 2
11
Recruiting
240
Score

Pipeline by Phase

Phase 3
3
Phase 2
13
Phase 1
17

Therapeutic Focus

NSCLC Breast Cancer Plaque Psoriasis Mass Balance Study Gout

Clinical Trials (28)

NCT06954961 Phase 3 RECRUITING

A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer

Started: 9/15/2022

NCT07326813 Phase 3 RECRUITING

A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis

Started: 1/12/2026

NCT07130604 Phase 3 RECRUITING

Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis

Started: 9/18/2025

NCT07311200 Phase 2 RECRUITING

A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)

Started: 2/12/2026

NCT07315061 Phase 2 RECRUITING

A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis

Started: 1/16/2026

NCT07035041 Phase 2 RECRUITING

A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis

Started: 5/22/2025

NCT07489885 Phase 2 NOT YET RECRUITING

A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis

Started: 5/1/2026

NCT06278350 Phase 2 COMPLETED

Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis

Started: 1/31/2024

NCT05665699 Phase 2 ACTIVE NOT RECRUITING

Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout

Started: 4/17/2023

NCT05504083 Phase 2 COMPLETED

Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients

Started: 9/28/2022

NCT03861156 Phase 2 COMPLETED

D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer

Started: 2/28/2019

NCT07270783 Phase 1 RECRUITING

Healthy Volunteer Study

Started: 12/4/2025

NCT07411742 Phase 1 ACTIVE NOT RECRUITING

Mass Balance Study of [14C] D-2570

Started: 3/10/2026

NCT07275775 Phase 1 COMPLETED

Single and Multiple Dose and Food Effect Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-2570 Tablets in Healthy Subjects

Started: 8/13/2024

NCT05379946 Phase 1 ACTIVE NOT RECRUITING

Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors

Started: 10/12/2022

NCT04585035 Phase 1 ACTIVE NOT RECRUITING

Study to Evaluate D-1553 in Subjects With Solid Tumors

Started: 10/2/2020

NCT05383898 Phase 1 COMPLETED

Study to Evaluate D-1553 in Subjects With Lung Cancer

Started: 3/16/2021

NCT05492045 Phase 1 TERMINATED

A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer

Started: 9/13/2022

NCT06105255 Phase 1 COMPLETED

A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553

Started: 5/24/2023

NCT06233916 Phase 1 COMPLETED

Mass Balance Study of [14C] D-1553 in Chinese Healthy Adult Male Subjects

Started: 12/8/2023

NCT03471663 Phase 1 COMPLETED

A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

Started: 3/18/2018

NCT03452150 Phase 1 COMPLETED

D-0316 First Time in Patients Ascending Dose Study

Started: 1/3/2018

NCT05339633 Phase 1 COMPLETED

Study in Healthy Adult Female Subjects

Started: 3/29/2022

NCT05226338 Phase 1 COMPLETED

Evaluation of Relative Bioavailability of D-0502 Tablet in Healthy Female Subjects

Started: 10/27/2021

NCT03923868 Phase 1 COMPLETED

D-0120 Safety and PK/PD Study in China

Started: 4/18/2019

NCT04097405 Phase 1 COMPLETED

Phase I Study of D-0120 to Evaluate Safety and PK/PD Study in Healthy Volunteers

Started: 9/18/2019

NCT03810625 Phase 1 COMPLETED

Food Effect Study of D-0502 Tablet in Healthy Volunteers

Started: 10/23/2018

NCT03291782 Phase 1 COMPLETED

D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers

Started: 9/13/2017

Drug Candidates

D-0502 Fulvestrant D-2570 Tablet Placebo Tablets [14C] D-2570 group BMS-986165 Tablet Placebo D-2570 D-2570 Placebo D-0120
Activity Status: Active
Last Trial Started: 5/1/2026
Last Trial Ended: 6/23/2025
Trials (12 months): 8
Completed Trials: 15
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.